Enzymatica AB

Quotes

ColdZyme is the future of cold relief. By breaking the viral cycle at the first signs of symptoms, the product helps cut illness duration in half and speeds up recovery.

Sana Alajmovic

We offer a unique, evidence-based alternative in a market dominated by outdated products. ColdZyme reduces viral load by 94 percent, helping you avoid putting your life on hold.

Sana Alajmovic

My focus is to lead Enzymatica into its next phase of growth. ColdZyme is a consumer favorite with clinically proven efficacy – we have the potential to become a global leader.

Sana Alajmovic

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Year-end report 2025: New CEO takes the helm – initiates the next phase of Enzymatica’s international expansion

Wed, Feb 18, 2026 08:30 CET

Fourth quarter January-December · Net sales · Net sales reached SEK 53.9 (45.6)reached SEK 18.3 million.(17.2) million · The operating result totaled SEK -51.4 ( · The operating -52.1) million.result totaled SEK · Earnings per share, basic and diluted,-10.2 (-13.7) were SEK -0.21 (-0.28).million. · Cash flow from operating activities for · Earnings per the period totaled SEK -41.0 (-60.5)share, basic and million.diluted, were SEK · Net cash totaled SEK 32.1 (73.0) million-0.05 (-0.05). at year-end. ·

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

Quotes

Year-end report 2025: New CEO takes the helm – initiates the next phase of Enzymatica’s international expansion

Subscribe